Category Archives: Uncategorized

Parion Sciences and Takeda End Collaboration on P-321 for Ophthalmic Indications

Durham, North Carolina – October 31, 2019 – Parion Sciences, Inc. today announced the termination of the License Agreement dated April 28, 2017 between Parion and Shire (now Takeda Pharmaceutical Company Limited) that granted Shire exclusive worldwide rights to develop and commercialize P-321.  As a result of the termination, Parion regains exclusive development and commercial rights to P-321 for all indications.

READ THE ENTIRE PRESS RELEASE HERE ►

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Demonstrates ongoing commitment to innovation in ophthalmics for Shire

P-321 is a Phase 2 investigational topical treatment for dry eye disease

Lexington, Massachusetts, and Durham, North Carolina, US – May 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.

READ THE ENTIRE PRESS RELEASE HERE ►